| Prev Close | 67.39 |
| Day Low/High | 66.78 / 67.94 |
| 52 Wk Low/High | 54.07 / 67.96 |
Bristol-Myers Squibb Company (BMY)
67.34
NYSE
| Exchange | NYSE |
| Shares Outstanding | 2233.93B |
| Market Cap | 150.54B |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
2 Biotech Stocks That Appear Undervalued Based on Their Prospects
Agenus Inc. and uniQure N.V. recently have announced positive news developments that should boost their long-term prospects.
Jim Cramer: Here's What Can Go Higher
Let's look at the companies that can go up, and the ones that can't.
Jim Cramer: Don't Bet Against Comebacks in This Second Chance Market
Just like you have to know how to read a room, you have to know how to read a tape and this tape screams 'I'm not done yet.'
Economics for Dummies, Fed Recap, Fun With Jobs Math, Amazon, Buying ServiceNow
The differences in approach between the two most basic strategies for how to grow an economy are as stark as the division they cause among economists.
A Blue Chip Healthcare Stock for Growth And Yield
Bristol-Myers offers a terrific combination of yield, dividend safety, and dividend growth for income-focused investors.
Is Bristol-Myers Squibb Finally Ready for a Breakout?
Prices have rallied from early March and are in a position to test their January highs.
Looking at Bristol-Myers Again as the Quants Downgrade It
At current levels BMY is sort-of in no man's land - not bullish and not bearish.
Here Are 2 Biotechs That Posted Strong Earnings
Exelixis and Ultragenyx Pharmaceutical are cash rich mid-caps that don't look overbought.
Turn of the Worm, Treasury Curve, Manchin's Might, Trading Microsoft, Spotify
There is a point where if longer-dated yields move high enough, defensive-minded investors will be drawn from equities to debt securities.
Jim Cramer: Looking for Gold? Go With Science
A potential breakthrough in Alzheimer's. A new device for blood pressure. More vaccines. These are opportunities to cheer in a time of turmoil.
Bristol-Myers Squibb Could Finally Make Its Move
Traders should stay long and consider increasing their exposure.
How to Play Emergent BioSolutions Right Now
A correction in EBS could soon set up an attractive opportunity.
The Week That Was, Q4 Earnings Expectations, Key Investor and Healthcare Events
This Friday several banks begin the unofficial kickoff of 'earnings season'.
How I'm Playing Astra-Zeneca on Vaccine and Acquisition News
I am staying away from this name for now, despite the Alexion acquisition and vaccine promise.
2 Potential Acquisition Targets as Biotech Deal Activity Picks Up
BioXcel Therapeutics and Avadel Pharmaceuticals would make good additions to the portfolios of larger drug companies.
This Trio of Diverse Stocks Makes for Interesting Stalking
The technical patterns of Boeing, Bristol-Myers Squibb and DraftKings are worth tracking for potential buys.
Eli Lilly: Back From the Depths
I am flat LLY for now. Let's see how the shares behave around the technicals. Then we'll make an equity decision.
Election Hindsight, Treasury Yields, Fed Day, Chip Stock Setup, A Great Trade
The most important market takeaway right now is that both the Nasdaq Composite and S&P 500 have filled their respective gaps and retaken their 50-day simple moving averages.
Jim Cramer: Let's Bust These Election Myths
These are the top five misconceptions about presidential elections -- and the stocks that you should look at right now.
Jim Cramer: Here's Why the President Is Gambling With Stimulus
The market is reflecting a triumph of big business over small business, and here's what that means for individual stocks.
Bristol-Myers Squibb Could Soon Break Out of a Large Triangle Pattern
Aggressive traders could go long BMY at two price levels.
Trump's Health and the Market, Charts That Matter, Nvidia News, URI Breaks Out
Even more important than fiscal support moving forward would be the concept of Covid-19 very soon being effectively treatable for the public.
Jim Cramer: Does Everyone Out There Perceive That Everything Is a Win?
It's remarkable to see such excitement based on totally contradictory theories and themes.
Does 'Aggressive' Bristol-Myers Have the Right Prescription for Investors?
BMY's announced acquisition of MyoKardia for $13B comes less than a year after its purchase of Celgene.
Jim Cramer: Diversification Is the Key to Getting Through This Market Upheaval
This diversification strategy lets you to capture stock market upside, while not risking your shirt.
A Healthy Dose of Vaccine and Pharmaceutical Plays
6 favorite stocks and ETFs in the biotech and pharmaceutical sector, including a diversified basket of Covid-19 vaccine names.
